Literature DB >> 18983272

Inconclusive results in conventional serological screening for Chagas' disease in blood banks: evaluation of cellular and humoral response.

Celia Regina Furuchó1, Eufrozina S Umezawa, Igor Almeida, Vera L Freitas, Rita Bezerra, Elisabete V Nunes, Maria C Sanches, Cristina M Guastini, Antonio R Teixeira, Maria A Shikanai-Yasuda.   

Abstract

OBJECTIVE: To find the most reliable screening method for Trypanosoma cruzi infection in blood banks.
MATERIAL AND METHODS: Epidemiological data, lymphoproliferation assay, parasitological, conventional serological tests: immunofluorescence, haemagglutination, ELISA with epimastigote and trypomastigote antigens and reference serological tests: trypomastigote excreted-secreted antigens (TESA) blot and chemiluminescent ELISA assay with mucine from trypomastigote forms were applied to individuals with inconclusive serology, non-chagasic individuals and chronic chagasic patients.
RESULTS: TESA blot had the best performance when used as a single test in all the groups. In the inconclusive group 20.5% of individuals were positive for TESA blot, 23.3% for either lymphoproliferation or TESA blot, and 17.8% for lymphoproliferation only. Positive lymphoproliferation without detectable antibodies was observed in 5.47% of all inconclusive serology cases. Analysis of six parameters (three serological assays, at least one parasitological test, one lymphoproliferation assay and epidemiological data) in the inconclusive group showed that diagnosis of Chagas' disease was probable in 15 patients who were positive by two or more serological tests or for whom three of those six parameters were positive.
CONCLUSION: TESA blot is a good confirmatory test for Chagas' disease in the inconclusive group. Although lymphoproliferation suggests the diagnosis of Chagas' disease in the absence of antibodies when associated with a high epidemiological risk of acquiring Chagas' disease, the data from this study and the characteristics of the lymphoproliferation assay (which is both laborious and time-consuming) do not support its use as a confirmatory test in blood-bank screening. However, our findings underscore the need to develop alternative methods that are not based on antibody detection to improve the diagnosis when serological tests are inconclusive.

Entities:  

Mesh:

Year:  2008        PMID: 18983272     DOI: 10.1111/j.1365-3156.2008.02172.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  14 in total

1.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

2.  Dealing with initial inconclusive serological results for chronic Chagas disease in clinical practice.

Authors:  J S Lapa; R M Saraiva; A M Hasslocher-Moreno; I Georg; A S Souza; S S Xavier; P E A A do Brasil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-08       Impact factor: 3.267

3.  Trypanosoma cruzi-specific immune responses in subjects from endemic areas of Chagas disease of Argentina.

Authors:  Gabriela C Olivera; Maria C Albareda; Maria G Alvarez; Ana M De Rissio; Laura E Fichera; Gretchen Cooley; Pedro Yachelini; Hugo A Hrellac; Hilda Riboldi; Susana A Laucella; Rick L Tarleton; Miriam Postan
Journal:  Microbes Infect       Date:  2010-02-01       Impact factor: 2.700

4.  Chronic Chagas Disease Diagnosis: A Comparative Performance of Commercial Enzyme Immunoassay Tests.

Authors:  Fred Luciano Neves Santos; Wayner Vieira de Souza; Michelle da Silva Barros; Mineo Nakazawa; Marco Aurélio Krieger; Yara de Miranda Gomes
Journal:  Am J Trop Med Hyg       Date:  2016-03-14       Impact factor: 2.345

5.  Performance of six diagnostic tests to screen for Chagas disease in blood banks andprevalence of Trypanosoma cruzi infection among donors with inconclusive serologyscreening based on the analysis of epidemiological variables.

Authors:  Gilberto de Araujo Pereira; Francisco Louzada-Neto; Valdirene de Fátima Barbosa; Márcia Maria Ferreira-Silva; Helio de Moraes-Souza
Journal:  Rev Bras Hematol Hemoter       Date:  2012

6.  Challenges and perspectives of Chagas disease: a review.

Authors:  Paulo Câmara Marques Pereira; Elaine Cristina Navarro
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2013-12-19

7.  Identification of strain-specific B-cell epitopes in Trypanosoma cruzi using genome-scale epitope prediction and high-throughput immunoscreening with peptide arrays.

Authors:  Tiago Antônio de Oliveira Mendes; João Luís Reis Cunha; Rodrigo de Almeida Lourdes; Gabriela Flávia Rodrigues Luiz; Lucas Dhom Lemos; Ana Rita Rocha dos Santos; Antônia Cláudia Jácome da Câmara; Lúcia Maria da Cunha Galvão; Caryn Bern; Robert H Gilman; Ricardo Toshio Fujiwara; Ricardo Tostes Gazzinelli; Daniella Castanheira Bartholomeu
Journal:  PLoS Negl Trop Dis       Date:  2013-10-31

8.  A general latent class model for performance evaluation of diagnostic tests in the absence of a gold standard: an application to Chagas disease.

Authors:  Gilberto de Araujo Pereira; Francisco Louzada; Valdirene de Fátima Barbosa; Márcia Maria Ferreira-Silva; Helio Moraes-Souza
Journal:  Comput Math Methods Med       Date:  2012-07-31       Impact factor: 2.238

9.  Highly discordant serology against Trypanosoma cruzi in central Veracruz, Mexico: role of the antigen used for diagnostic.

Authors:  Daniel Guzmán-Gómez; Aracely López-Monteon; María de la Soledad Lagunes-Castro; Carolina Álvarez-Martínez; Manuel Jesús Hernández-Lutzon; Eric Dumonteil; Angel Ramos-Ligonio
Journal:  Parasit Vectors       Date:  2015-09-17       Impact factor: 3.876

10.  Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment.

Authors:  Cynthia Santamaria; Eric Chatelain; Yves Jackson; Qianqian Miao; Brian J Ward; François Chappuis; Momar Ndao
Journal:  BMC Infect Dis       Date:  2014-06-03       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.